A Game-Changer for Early Detection and Personalized Treatment
Eye cancer may be rare, but its impact on patients’ lives is profound. In a groundbreaking initiative, Roche Diagnostics is teaming up with the University of Liverpool to launch EYE-CAN-AID—a cutting-edge AI-powered digital bioresource designed to enhance early detection, diagnosis, and treatment of rare ocular cancers.
A New Era in Eye Cancer Research
EYE-CAN-AID is more than just a database; it’s a multi-modal image repository that securely stores clinical images, histological data, genetic profiles, and radiological scans from consenting patients across the UK. By integrating this wealth of information, the initiative aims to:
Advance research into the causes of rare eye cancers
Develop predictive biomarkers for personalized treatments
Improve early detection and diagnosis for better patient outcomes
Powered by AI and Digital Pathology
At the heart of this innovation are Roche Diagnostics’ VENTANA DP 600 digital pathology slide scanners, which digitize tissue samples with high-resolution imaging. These scanners work in tandem with AI-powered image analysis to improve accuracy, accelerate diagnosis, and support the development of novel personalized treatment strategies.
Expanding Across the UK
Building on a 14-year-old eye cancer biobank, EYE-CAN-AID will now integrate data from the UK’s three specialist eye cancer centers in Liverpool, Sheffield, and London, creating a national network of expertise.
Professor Sarah Coupland, Director of the Liverpool Ocular Oncology Research Group (LOORG), emphasized the collaborative impact:
“By uniting clinicians, researchers, industry, and charities, we’re advancing our understanding of eye cancer, its causes, and treatments.”
Luke Benko, International Business Leader for Digital Pathology at Roche Diagnostics, echoed this sentiment:
“Our collaboration has created a first-of-its-kind digital repository for rare eye cancer, providing an equitable and accessible resource to the scientific community.”
A Critical Step Toward Saving Sight and Lives
With 1,000 new eye cancer cases in the UK annually—and a mortality rate as high as 50%—this initiative is a major leap forward in fighting a disease that threatens not just vision but lives. By harnessing AI, digital pathology, and collaborative research, EYE-CAN-AID has the potential to reshape the future of eye cancer diagnosis and treatment, offering hope to thousands of patients.
A Shared Vision for the Future
Through this collaboration, Roche and the University of Liverpool are pioneering a smarter, data-driven approach to rare cancers, proving that when technology and research unite, life-saving innovations follow.